Figure 1
Evidence for GVL activity in a patient with CLL. CD19 ϩ CD5 ϩ CD20 dim CLL cells can be demonstrated by flow cytometry in the peripheral blood immediately prior to and during the first 4 months post SCT as illustrated by the curve. With the onset of chronic GVHD after cyclosporin withdrawal, CLL cell counts decline and become undetectable at 6 months. Simultaneously, the clonal CDR3 PCR signal disappears.
intensity regimen can be associated with relevant complications and should not be administered uncritically. In particular acute and chronic GVHD continues to be a problem. Ex vivo or in vivo T cell depletion might provide a solution to this but may be associated with detrimental effects on engraftment, immune reconstitution, and GVL activity. 7, 8 Thus, controlled prospective trials are warranted to assess if allo-SCT with dose-reduced conditioning can indeed improve the outcome of patients with lymphoma relapse after autografting.
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Departments tinuation and histological evaluation revealed characteristic bile duct abnormalities and portal inflammation. In the discussion, Busca et al stated: 'to our knowledge, severe liver toxicity related to MMF has been reported in one study only 5 '. We would like to stress that the safety profile of mycophenolate mofetil in the setting of hematopoietic stem cell transplantation should be further evaluated. In our paper published in the May 1998 issue of Bone Marrow Transplantation 2 we stated that no nephrotoxicity or liver toxicity were noted in our patients except for one, who had extensive cGVHD and developed progressive liver toxicity on MMF therapy. However, the progressive liver toxicity in this particular patient was most likely to have been due to progressive multiorgan failure rather than to MMF. Indeed, this patient died from progressive multiorgan failure related to extensive chronic GVHD and the treatment with MMF was an attempt to improve the patient's condition. The paper by Busca et al raises the critical issue of differentiating the adverse effects of MMF from the clinical signs of severe GVHD; very few studies have addressed the issue of the effect of MMF in the treatment of GVHD (Table 1) , however addressing primarily the efficacy of MMF. MMF is an immunosuppressant that selectively inhibits proliferation of T-and B-lymphocytes and is successfully used for the prevention of acute rejection in primary cadaveric renal allograft recipients. 3, 4 The study of the US Renal Transplant Mycophenolate Mofetil Study Group 3 demonstrated that MMF administered at a dosage of 2 g is better tolerated compared with 3 g. The most frequently reported adverse events were anemia, hypertension and diarrhea. In addition, esophagitis, gastritis and gastrointestinal hemorrhages were observed. The tricontinental mycophenolate mofetil renal transplantation study group reported similar adverse effects, 4 these being more severe in patients receiving MMF 3 g. No other specific organ toxicity was observed in either treatment group (MMF 2 g and MMF 3 g). The most common adverse event in pediatric renal transplant recipients was anemia, and only a small percentage of patients developed diarrhea and leukopenia. 5 In addition MMF is used successfully for the treatment 1,2,6,7 and prophylaxis 8, 9 of acute GVHD after hematopoietic stem cell transplantation. The safety profile of MMF in hematopoietic stem cell transplantation revealed 8 that the relative scores for renal, cardiac pulmonary and hepatic toxicity were comparable in the group of patients receiving MMF/CsA and those receiving MTX/CsA for the prophylaxis of GVHD.
In conclusion, we would like to stress that the frequency of adverse events observed in different studies of MMF in the treatment and prophylaxis of GVHD appear to be low, thus resulting in good patient compliance. The favorable toxicity profile and steroid-sparing effect of MMF should be considered in decision-making with regard to the treatment and prophylaxis of severe GVHD.
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